Cboe BZX
02:04:16 2024-04-24 pm EDT
5-day change
1st Jan Change
64.17
USD
-0.09%
+1.73%
+12.98%
LeMaitre Vascular, Inc. agreed to acquire Jisan General Construction Co., Ltd. for KRW 5.40 million.
LeMaitre Vascular, Inc. (NasdaqGM:LMAT) agreed to acquire Jisan General Construction Co., Ltd. for KRW 5.40 million on April 28, 2022.
Lemaitre Vascular Insider Sold Shares Worth $309,684, According to a Recent SEC Filing
Mar. 12
MT
Lemaitre Vascular Insider Sold Shares Worth $344,925, According to a Recent SEC Filing
Mar. 07
MT
Lemaitre Vascular Insider Sold Shares Worth $517,500, According to a Recent SEC Filing
Mar. 07
MT
Health Care Drops After Mixed Earnings -- Health Care Roundup
Feb. 28
DJ
Barrington Raises Price Target on LeMaitre Vascular to $69 From $66, Keeps Outperform Rating
Feb. 28
MT
LeMaitre Vascular, Inc. Approves Quarterly Dividend, Payable on March 28, 2024
Feb. 27
CI
LeMaitre Vascular, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024
Feb. 27
CI
LeMaitre Vascular, Inc. announces an Equity Buyback for $50 million worth of its shares.
Feb. 27
CI
LeMaitre Vascular, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Feb. 27
CI
Transcript : LeMaitre Vascular, Inc., Q4 2023 Earnings Call, Feb 27, 2024
Feb. 27
(LMAT) LEMAITRE VASCULAR Forecasts Fiscal Year 2024 EPS $1.65
Feb. 27
MT
(LMAT) LEMAITRE VASCULAR Expects Q1 EPS $0.28
Feb. 27
MT
Earnings Flash (LMAT) LEMAITRE VASCULAR Reports Q4 Revenue $48.9M, vs. Street Est of $49M
Feb. 27
MT
LeMaitre Vascular, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Feb. 27
CI
LeMaitre Vascular, Inc. authorizes a Buyback Plan.
Feb. 20
CI
Tranche Update on LeMaitre Vascular, Inc.'s Equity Buyback Plan announced on February 23, 2023.
Nov. 07
CI
Transcript : LeMaitre Vascular, Inc., Q3 2023 Earnings Call, Nov 01, 2023
Nov. 01
Earnings Flash (LMAT) LEMAITRE VASCULAR Posts Q3 Revenue $47.4M, vs. Street Est of $47.6M
Nov. 01
MT
LeMaitre Vascular, Inc. Approves Quarterly Dividend, Payable on November 30, 2023
Nov. 01
CI
LeMaitre Vascular, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 01
CI
JMP Securities Initiates LeMaitre Vascular With Market Outperform Rating, Price Target is $60
23-10-23
MT
Oppenheimer Initiates Coverage on LeMaitre Vascular With Outperform Rating, $70 Price Target
23-09-06
MT
Tranche Update on LeMaitre Vascular, Inc.'s Equity Buyback Plan announced on February 23, 2023.
23-08-08
CI
North American Morning Briefing : Stocks Seen -2-
23-08-04
DJ
Jefferies Downgrades LeMaitre Vascular to Hold From Buy, Adjusts Price Target to $67 From $63
23-08-03
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Its portfolio of product lines is primarily used to treat vascular disease, of which most are used in open vascular surgery and dialysis access. It also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy catheters, occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. The Companyâs principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. The Company sells its products and services primarily through a direct sales force.
More about the company
Last Close Price
64.23
USD
Average target price
71.29
USD
Spread / Average Target
+10.99%
Consensus
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
LEMAITRE VASCULAR, INC. 
